Observational studyEuropean heart journal. Acute cardiovascular care2026
Advanced reperfusion therapies for acute pulmonary embolism in pregnancy and postpartum.
Observational study in European heart journal. Acute cardiovascular care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsPulmonary embolism (PE) remains the leading preventable cause of maternal death in high-income countries. Data on the management of acute PE during pregnancy are limited because pregnant women are systematically excluded from interventional trials. We evaluated the use and outcomes of advanced reperfusion therapies in pregnancy-associated PE.
methodsWe performed a cross-sectional analysis of the US Nationwide Inpatient Sample from 2016 through 2020. Pregnancy- and puerperium-related hospitalizations were identified using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. High-risk PE was defined by shock, mechanical ventilation, cardiac arrest, cardiopulmonary resuscitation, or vasopressor support. Advanced reperfusion therapies included systemic thrombolysis (ST), catheter-directed therapy (CDT), surgical embolectomy, and venoarterial extracorporeal membrane oxygenation (VA-ECMO).
resultsAmong 19 741 880 pregnancy- or puerperium-related hospitalizations, 12 715 (0.06%) were complicated by PE, corresponding to 6.7 (95% CI, 6.6-6.8) hospitalizations per 10 000 live births. The overall in-hospital mortality rate was 0.86% (0.058 [95% CI, 0.048-0.070] deaths per 10 000 live births). Mortality was 0.2% among patients without haemodynamic instability and 29.1% among those with high-risk PE. Advanced reperfusion therapies were used in 3.4% of all pregnancy-associated PE cases and in 32.7% of high-risk cases. In-hospital mortality was 9.8% after ST, 10.7% after CDT, and 50% after VA-ECMO. Major bleeding occurred in 15.7%, 10.7%, and 50%, respectively.
conclusionPregnancy-associated PE is rare but associated with high mortality in high-risk presentations. Advanced reperfusion therapies are used infrequently, reflecting the limited evidence, highlighting the need for multidisciplinary management, and further research and guidance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.